April 2 (Reuters) - Nurix Therapeutics Inc NRIX.O:
NURIX LICENSES A DRUG DISCOVERY PROGRAM TO SANOFI TARGETING A NOVEL TRANSCRIPTION FACTOR FOR AUTOIMMUNE DISEASES
NURIX THERAPEUTICS- RECEIVES $15 MILLION LICENSE EXTENSION FEE FROM SANOFI
NURIX THERAPEUTICS- ELIGIBLE FOR ADDITIONAL $465 MILLION IN MILESTONES AND ROYALTIES
Source text: ID:nGNXp0z2
Further company coverage: NRIX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.